Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
CellCentric logo — Developing inobrodib (CCS1477), first-in-class p300/CBP inhi...

CellCentric

Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.

Founded 2003 United Kingdom Cambridge, United Kingdom 23 employees Series Unknown Total: $96.54M Biotechnology, Health and Wellness

General Information

Company Name CellCentric
Founded Year 2003
Location United Kingdom Cambridge, United Kingdom +1
Employees 23
Industries Biotechnology, Health and Wellness
Funding Stage Series Unknown
Social

Get notified when CellCentric moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CellCentric

CellCentric is a UK-based biotechnology startup founded in 2003 that is making waves in the field of cancer treatment. Their slogan, "Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers," encapsulates their mission. The company's key focus is on inobrodib, the first small molecule drug targeting twin proteins p300 and CBP. This drug is currently in Phase I/II clinical trials, showing promise in treating specific solid tumors and haematological malignancies, addressing critical unmet medical needs in cancer treatment. The latest milestone for CellCentric was a $25.00M Corporate Round investment on 11 July 2023, with Pfizer among the investors. This injection of funding marks a pivotal point in the company's journey, providing the means to further advance their groundbreaking drug and potentially revolutionize cancer therapy. With their pioneering approach and a strong backing from established industry players, CellCentric is at the forefront of developing innovative solutions that could significantly impact the future of cancer treatment.

Taxonomy: Cancer Therapy, Clinical Trials, Oral Medication, Small Molecule Drug, p300/CBP Inhibitor, Solid Tumors, Haematological Malignancies, Gene Activating Proteins, Phase I/II, Clinical Unmet Needs

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round £27.16M 1
RA Capital Management
24 Jul 2024
Venture Round Unknown 2
Morningside Venture Partners
BrightEdge Fund 		26 Jan 2022
Venture Round $33.00M 1 Morningside Venture Investments 22 Oct 2020
Venture Round $26.00M 1
Morningside Venture Partners
15 May 2018
Venture Round Unknown 1
Nesta Ventures
01 Jun 2017

View All 15 Funding Rounds

CellCentric Alternatives & Competitors

CellCentric vs
Cellestia Biotech
Cellestia Biotech Switzerland

Cellestia develops targeted therapies for cancer patients with no other options, including orphan ca...

Non Equity Assistance
15 employees
Biopharma, Biotechnology
CellCentric vs
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals United States

TARGETING DIFFICULT TO TREAT CANCERS

Post Ipo Equity
7 employees
Biotechnology, Medical Devices
CellCentric vs
Meinox Pharma Technologies
Meinox Pharma Technologies Turkey

Next generation personalized therapeutics to fight cancer

1 employees
Health and Wellness, Pharmaceutical

FAQ About CellCentric

Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.
CellCentric was founded in 2003.
CellCentric is headquartered in Cambridge, United Kingdom.
CellCentric operates in the following industries: Biotechnology, Health and Wellness.
CellCentric has approximately 23 employees.
CellCentric has completed 15 funding rounds, raising a total of $96.54M. The latest funding stage is Series Unknown.
Top alternatives and competitors to CellCentric include Cellestia Biotech, Rexahn Pharmaceuticals, Meinox Pharma Technologies, Kronos Bio, Salmedix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CellCentric and Cellestia Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CellCentric and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy